Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| (b) | Departure of Certain Officers. |
On June 26, 2017, Lucy Lu, M.D. resigned as Chief Financial
Officer of Fortress Biotech, Inc. (the Company).
| (c) | Appointment of Certain Officers. |
On June 26, 2017, Robyn Hunter, 55, was appointed as the Companys
Chief Financial Officer.
Ms. Hunter has more than 30 years of financial and operational
experience in an array of industries. Since June 2011, Ms. Hunter
has served as the Companys Vice President and Corporate
Controller where she has implemented financial and operational
processes, procedures and policies to facilitate the Companys
execution of its growth strategy. From January 2006 to May 2011,
Ms. Hunter served as Senior Vice President and Chief Financial
Officer of Schochet Associates. From August 2004 to January 2006,
Ms. Hunter served as the Corporate Controller for Indevus
Pharmaceuticals. From 1990 to 2004, Ms. Hunter held several
positions from Accounting Manager to Vice President and Treasurer
of The Stackpole Corporation. Ms. Hunter holds a Bachelor of Arts
degree in Economics from Union College in Schenectady New York.
No family relationships exist between Ms. Hunter and any of the
Companys directors or other executive officers. There are no
arrangements between Ms. Hunter and any other person to which Ms.
Hunter was selected as an officer, nor are there any transactions
to which the Company is or was a participant and in which Ms.
Hunter has a material interest subject to disclosure under Item
404(a) of Regulation S-K.
About Fortress Biotech, Inc. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
